Seeking participants for a new Crohn's Disease study

We are evaluating the efficacy and safety of Filgotinib in the induction and maintenance of remission in people with moderately to severely active Crohn’s Disease

Crohn’s disease is an inflammatory disease of the gastrointestinal tract (digestive tract).  The purpose of this study is to see if filgotinib, an experimental drug, is effective and safe in treating people with moderate to severe Crohn’s disease.

Anticipated date that enrolment will close: 31 December 2022

Who can take part

  • People who have been diagnosed with Crohn's Disease for at least 6 months; and
  • People of reproductive potential must be willing to adhere to specified contraceptive methods

What is involved for you

  • electro cardiograms (ECGs)
  • vital signs will be taken (blood pressure, respiratory rate, heart rate), height , weight
  • ileocolonoscopy (with Biopsies)
  • urine sample
  • stool sample
  • blood samples
  • questionnaires
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
Zafirah Khan
(03) 9342 7798
Nicole Tresize
(03) 9342 8411